Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Stemtech (STEK) Shares Outstanding (Diluted Average) (2021 - 2025)

Stemtech's Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $150.1 million for Q3 2025.

  • On a quarterly basis, Shares Outstanding (Diluted Average) rose 30.97% to $150.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $150.1 million, a 30.97% increase, with the full-year FY2024 number at $118.7 million, up 42.2% from a year prior.
  • Shares Outstanding (Diluted Average) hit $150.1 million in Q3 2025 for Stemtech, up from $140.2 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for STEK hit a ceiling of $150.1 million in Q3 2025 and a floor of $19.1 million in Q3 2021.
  • Historically, Shares Outstanding (Diluted Average) has averaged $76.8 million across 5 years, with a median of $76.2 million in 2023.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): soared 279.07% in 2021 and later increased 20.07% in 2025.
  • Tracing STEK's Shares Outstanding (Diluted Average) over 5 years: stood at $35.3 million in 2021, then soared by 30.31% to $46.0 million in 2022, then soared by 81.4% to $83.5 million in 2023, then surged by 42.2% to $118.7 million in 2024, then rose by 26.46% to $150.1 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for STEK at $150.1 million in Q3 2025, $140.2 million in Q2 2025, and $118.7 million in Q1 2025.